Collaborations are critical to our own success and the success of the industry.
Creating Partnerships that Make a Difference
At AbbVie, we partner to achieve two important outcomes: deliver innovative medicines and make a remarkable impact on people’s lives.
We start with a highly integrated approach to developing and sustaining our partnerships. We work as one connected unit with a commitment to establishing collaborations across the development continuum that will ultimately benefit patients and fuel scientific progress.
Whether partnering with a business, academia or consortia, our goal is to create long-term mutually beneficial relationships. For example, for a smaller biotech partner, AbbVie’s global medical affairs and commercial reach may enable their product to benefit patients worldwide. Large pharmaceutical partnerships allow each company to contribute the strengths of their organization.
With a shared vision as our foundation, we align our capabilities to conduct groundbreaking science and bring innovative medicines to societies around the globe. From start to finish, we manage our partnerships for success—from early identification and mitigation of risks to shared accountability and reward for successful outcomes. Our partners and our strong team help make this possible.
How We Work Together
Business Development and Acquisitions
Our business development team evaluates a variety of partnership structures to meet the needs of both parties. They work closely with our commercial and R&D organizations to evaluate new opportunities that complement and enhance our existing internal innovation strategy.
Highly successful partnerships result from an ongoing commitment to realize a shared vision. At AbbVie, we have a dedicated team that is involved in all aspects of the partnership from contracting through commercialization to ensure positive outcomes for all parties.
We strategically invest in transformational scientific opportunities to augment our core R&D interests and gain access to next-generation science and proven scientific leaders. Our expertise in drug development and commercialization can be a valuable resource to even the earliest stage companies.
The Partnerships Team
Our team is ready to meet with you to share our capabilities and discuss your business opportunities. We are always looking for innovation and new partnership opportunities that align with our focus areas. With offices in the Northern California, Chicago and Boston areas, as well as other locations around the world, we look forward to hearing from you.
Contact us to learn more.
Search & Evaluation
Kevin Lynch, Ph.D., Vice President, Search & Evaluation
Hamish Allen, Ph.D., Immunology
David Calderwood, Ph.D., Immunology
Mary Chamberlain-Tharp, Ph.D., Academics
Jack Chen, Ph.D., Immunology
Milagros Colon-Lopez, Ph.D., Neuroscience, Renal
Niels Emmerich, Ph.D., Oncology
Murali Gopalakrishnan, Ph.D., Neuroscience
Adam Houghton, Ph.D., Immunology
Business Development & Acquisitions
Jay Stamatis, Vice President, Head of Business Development & Acquisitions
Tony Brazda, Neuroscience, Renal
John FitzGerald, Immunology
Ben Julian, Oncology, Hepatology
Suzanne A. Lebold, Ph.D., Immunology
Siobhan Pomeroy, Immuno-Oncology
Rahul Jerath, Oncology
Anna Maroney, Ph.D., Vice President, Alliance Management
Jonathan Kern, Ph.D., Oncology, Immunology, Renal
John Larson, Late-Stage Alliances
Jason Powell, Immunology
Shankar Subramanian, Ph.D., Early-Stage Alliances
Sheila Westmoreland, Neuroscience
Scott Brun, M.D., VP and Head, AbbVie Ventures
Margarita Chavez, Chicago and San Francisco area
John Gustofson, Ph.D., Boston/Cambridge area
Chuck Kunsch, Ph.D., Boston/Cambridge area
Ross Leimberg, Boston/Cambridge area
Priyanka Rohatgi, Ph.D., Chicago area